Moderna, Inc. (MRNA): Shareholders' Equity
$8.65B
As of 2025-12-31
$6.76B
As of 2026-06-30
-23.2%
3-year compound annual growth
+27.6%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $8.65B | -20.6% | 2026-02-20, Balance as of period end |
| 2024-12-31 | $10.90B | -21.3% | 2026-02-20, Balance as of period end |
| 2023-12-31 | $13.85B | -27.6% | 2026-02-20, Balance as of period end |
| 2022-12-31 | $19.12B | +35.2% | 2025-02-21, Balance as of period end |
| 2021-12-31 | $14.14B | +452.3% | 2024-02-23, Balance as of period end |
| 2020-12-31 | $2.56B | +118.0% | 2023-02-24, Balance as of period end |
| 2019-12-31 | $1.18B | -23.2% | 2022-02-25, Balance as of period end |
| 2018-12-31 | $1.53B | n/m | 2021-02-26, Balance as of period end |
| 2017-12-31 | -$551.37M | n/m | 2020-02-27, Balance as of period end |
| 2016-12-31 | -$334.81M | n/a | 2019-03-13, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Moderna, Inc. (MRNA) | 2025-12-31 | $8.65B | -20.6% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $3.78B | +5.9% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $2.16B | -3.7% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $48.81M | -86.6% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $3.25B | +25.6% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $2.11B | +9.9% |
| Novavax Inc (NVAX) | 2025-12-31 | -$127.75M | n/m |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | -$119.15M | n/m |
| Repligen Corp (RGEN) | 2025-12-31 | $2.11B | +6.8% |
Compare MRNA, QGEN, EXEL, HALO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗